To explore the potential impact of GLP-1 receptor agonists on glaucoma management and their neuroprotective effects.
Key Findings:
Patients using GLP-1 receptor agonists showed a lower risk of developing POAG compared to metformin users.
GLP-1 receptor agonists have neuroprotective and anti-inflammatory properties.
The observed benefit in glaucoma risk appeared relatively early in GLP-1 users.
Interpretation:
The findings suggest that GLP-1 receptor agonists may stabilize vascular autoregulation and modulate neuroinflammatory pathways, potentially influencing the early stages of glaucoma.
Limitations:
The study was observational, and causality cannot be inferred.
Metformin also has neuroprotective effects, complicating direct comparisons.
Conclusion:
GLP-1 receptor agonists may have significant implications for glaucoma care, warranting further investigation into their role beyond diabetic retinopathy.
